Troglitazone and Small Low-Density Lipoprotein in Type 2 Diabetes
Authors: Tsutomu Hirano
Journal: Annals of Internal Medicine (1998)

Letters15 July 1998Troglitazone and Small Low-Density Lipoprotein in Type 2 DiabetesTsutomu Hirano, MD, Gen Yoshino, MD, and Tsutomu Kazumi, MDTsutomu Hirano, MDShowa University School of Medicine; Tokyo, JapanToho University School of Medicine; Tokyo, JapanIlyogo Rehabilitation Center Hospital; Tokyo, Japan, Gen Yoshino, MDShowa University School of Medicine; Tokyo, JapanToho University School of Medicine; Tokyo, JapanIlyogo Rehabilitation Center Hospital; Tokyo, Japan, and Tsutomu Kazumi, MDShowa University School of Medicine; Tokyo, JapanToho University School of Medicine; Tokyo, JapanIlyogo Rehabilitation Center Hospital; Tokyo, JapanAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-2-199807150-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Several recent studies suggest the association of a preponderance of small, dense low-density lipoprotein (LDL) particles, potent atherogenic lipoproteins, with insulin resistance [1, 2]. However, it is still unknown whether insulin resistance or other factors related to insulin resistance directly regulate LDL size. We evaluated the direct association between insulin resistance and LDL size by treating patients with troglitazone, a new oral hypoglycemic agent [3] that ameliorates insulin resistance in patients with type 2 diabetes mellitus [4].Thirty patients who had type 2 diabetes treated with sulfonylurea were enrolled in this study. The levels of fasting plasma ...References1. Reaven GM, Chen Y-DI, Jeppesen J, Mahcux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest. 1993; 92:141-6. Google Scholar2. Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP, Mayer EJ, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation. 1993; 88:381-7. Google Scholar3. Fijiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988; 37:1549-58. Google Scholar4. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991; 14:1083-6. Google Scholar5. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982; 23:97-104. Google Scholar Author, Article, and Disclosure InformationAuthors: Tsutomu Hirano, MD; Gen Yoshino, MD; Tsutomu Kazumi, MDAffiliations: Showa University School of Medicine; Tokyo, JapanToho University School of Medicine; Tokyo, JapanIlyogo Rehabilitation Center Hospital; Tokyo, Japan PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMeasuring biomarkers to assess the therapeutic effects of PPAR agonists?Impact of thiazolidenediones on serum lipoprotein levelsDiacylglycerol oil ingestion in type 2 diabetic patients with hypertriglyceridemiaPeroxisome Proliferator-Activated Receptor-?? Agonists for Management and Prevention of Vascular Disease in Patients with and without Diabetes MellitusPPARγ and atherosclerosisTherapeutical effects of PPAR agonists assessed by biomarker modulationNuclear Peroxisome Proliferator-Activated Receptors and ThiazolidinedionesGlitazones and the management of insulin resistance: what they do and how might they be usedThiazolidinediones as PPAR AgonistsFavorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 DiabetesRelationship between the Presence of Small, Dense Low-density Lipoprotein and Plasma Lipid Phenotypes in Japanese ChildrenNiacin treatment of the atherogenic lipid profile and Lp(a) in diabetesComparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitusAtherogenic Lipid Phenotype and Lipoprotein (a) in DiabetesDifferential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 DiabetesAtherogenic lipoproteins and diabetes mellitusMetabolic and Additional Vascular Effects of ThiazolidinedionesTreatment of Small Dense LDLNew Oral Therapies for Type 2 Diabetes Mellitus: The Glitazones or Insulin SensitizersThiazolidinediones, dyslipidaemia and insulin resistance syndromeAnalysis: Antidiabetic Drugs and the Vascular System 15 July 1998Volume 129, Issue 2Page: 162-163KeywordsBlood plasmaGel electrophoresisGlucoseHemoglobinHypoglycemicsInsulinInsulin resistanceLipoproteinsLow density lipoproteinType 2 diabetes ePublished: 15 August 2000 Issue Published: 15 July 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...